Kymera Therapeutics, Inc.·4

Jan 6, 4:40 PM ET

Mainolfi Nello 4

4 · Kymera Therapeutics, Inc. · Filed Jan 6, 2026

Insider Transaction Report

Form 4
Period: 2026-01-05
Mainolfi Nello
DirectorChief Executive Officer
Transactions
  • Exercise/Conversion

    Common Stock

    2026-01-05$32.07/sh+3,118$99,994666,195 total
  • Exercise/Conversion

    Stock Option (Right to Buy)

    2026-01-053,118446,882 total
    Exercise: $32.07Exp: 2033-03-01Common Stock (3,118 underlying)
Footnotes (1)
  • [F1]The shares underlying this stock option shall vest in thirty-six (36) equal monthly installments following March 1, 2023, subject to the reporting person's continued employment through each vesting date.

Documents

1 file
  • 4
    ownership.xmlPrimary

    4